Exelixis CEO Presents at UBS Global Healthcare Conference (Transcript)
InPlay: Exelixis issues reminder that cabozantinib to be featured in nine presentations at 2013 ASCO Annual MeetingMay 15
Exelixis, Inc. reiterated its slate of activities in conjunction with the 2013 American Society of Clinical Oncology Annual Meeting, which will be held May 31-June 4, 2013, in Chicago, Illinois.
The overall ratings of seven Biotechnology stocks are down on Portfolio Grader this week. Each of these rates a "D" ("sell") or "F" overall ("strong sell").
Exelixis' CEO Presents at Bank of America Merrill Lynch Health Care Conference (Transcript)
Exelixis, Inc. announced today that Michael M. Morrissey, Ph.D., the company’s president and chief executive officer, will present at two investor conferences this mo
A biotech with a potentially game-changing drug, a treasure hunter, and a green-energy-for-hire company make this week's list of those worth keeping a close eye on.
In trading on Wednesday, shares of Exelixis Inc crossed above their 200 day moving average of $4.83, changing hands as high as $4.94 per share. Exelixis Inc shares are currently trading up about 7.4% on the day.
This week, the ratings of seven Biotechnology stocks on Portfolio Grader are down. Each of these rates a "D" ("sell") or "F" overall ("strong sell").
Exelixis' CEO Discusses Q1 2013 Results - Earnings Call Transcript